PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Clinical trial NCT03993379 · TERMINATED
Trial details
- NCT number
- NCT03993379
- Sponsor
- CytomX Therapeutics
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-20
- Primary completion
- 2020-05-21
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.